RxDoctor Payments Data

Jennifer Wilkerson, MD

Internal Medicine · Dallas, TXNPI 1982617239

Payments from drug & device makers

$6,763in general payments, 2019–2025

Across 332 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$890
  • Amarin Pharma, Inc.$715
  • Novo Nordisk$611
  • Abbott$430
  • Novartis$390
  • Lilly USA, LLC$389
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,757100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,763 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,548
Medicare patients
199
Services billed
1,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$96,898
EliquisApixaban48$35,935
MounjaroTirzepatide26$28,251
AmbienZolpidem Tartrate14$13,511
MyrbetriqMirabegron18$13,340
FarxigaDapagliflozin Propanediol15$12,887
RybelsusSemaglutide12$11,343
ProtonixPantoprazole Sodium12$10,483
XareltoRivaroxaban18$10,236
JardianceEmpagliflozin11$5,618
SynthroidLevothyroxine Sodium58$5,304
Estradiol52$3,284
Memantine Hcl ErMemantine Hcl19$2,481
Duloxetine Hcl53$1,897
Atorvastatin Calcium198$1,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$611$108,24193 claims
PfizerEliquis, Protonix, Paxlovid$338$47,78693 claims
Lilly USA, LLCMounjaro$389$28,25126 claims
Sanofi-aventis U.S. LLCAmbien$242$13,51114 claims
Astellas Pharma US IncMyrbetriq$221$13,34018 claims
AstraZenecaFarxiga$159$12,88715 claims
Johnson & JohnsonXarelto$167$10,23618 claims
Boehringer IngelheimJardiance$103$5,61811 claims
AbbVieSynthroid$382$5,30458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →